Skip to main content

Branded

  • Pfizer acquires Bamboo Therapeutics

    NEW YORK — In a move aimed at bolstering its position in the gene therapy field, Pfizer on Monday announced its acquisition of Bamboo Therapeutics. The Chapel Hill, N.C.-based company focuses on developing gene therapies for patients with rare diseases related to neuromuscular and central nervous system conditions. 
     

  • FDA approves ACE inhibitor oral solution Qbrelis

    SILVER SPRING, Md. — The Food and Drug Administration has approved Silvergate Pharmaceuticals’ Qbrelis (lisinopril) oral solution, the company announced Friday. Qbrelis is the first and only FDA-approved oral solution of the ACE inhibitor lisinopril indicated to treat hypertension in adults and pediatric patients 6 years of age and older, the company said.
     

  • FDA approves new Dysport indication

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Ipsen Biopharmaceuticals’ Dysport (abobotulinumtoxinA), the company announced Monday. The drug can now be used to treat lower limb spasticity in pediatric patients ages 2 years and older. 
     

  • Comfort Vision introduces 90-pack ProOcular Daily Contact Lenses

    CARLSBAD, Calif. -- Comfort Vision has added a 90-Pack configuration for ProOcular daily disposable contact lenses.

    The company says the lenses provide patients with the benefits of trusted polymacon material and the advantages of a unique Duel Aspheric Lens design -- resulting in a healthier and more comfortable contact lens-wearing experience.

  • Sanofi Pasteur to start shipping new flu vaccines

    SWIFTWATER, Pa. – Sanofi Pasteur on Tuesday announced today that its first doses of Fluzone  for the 2016-2017 influenza season have been released by the U.S. Food and Drug Administration for shipment.
    In the 2015-2016 influenza season, 50% of seniors who were vaccinated received Fluzone High-Dose vaccine, and this number is expected to rise to 60% in the coming season.

  • Octreotide Acetate Injection now available from Teva

    NORTH WALES, Pa. -- Teva announced that its Octreotide Acetate Injection, 50 mcg/mL, is back in stock and ready to order.

    The product is AP rated to Sandostatin (octreotide acetate) Injection. Teva now offers Octreotide Acetate Injection in 50 mcg/mL,100 mcg/mL, 200 mcg/mL, 500 mcg/mL, and 1000 mcg/mL.

     

     

  • NCPA forms Innovation Center to drive healthcare evolution through independent pharmacy

    ALEXANDRIA, Va. - The National Community Pharmacists Association on Tuesday announced the establishment of a new Innovation Center that is intended to further assist and speed up the evolution of independent community pharmacies in a changing health care environment.

  • NACDS joins 37 Congress leaders in supporting TRICARE cost-saving dispensing pilot

    ARLINGTON, Va. – The National Association of Chain Drug Stores on Wednesday publicly thanked the 37 members of the U.S. House of Representatives who have sent a letter to House and Senate negotiators, urging them to advance a TRICARE pilot program as part of the FY2017 National Defense Authorization Act.

X
This ad will auto-close in 10 seconds